Apalutamide as a new option for postponing metastatic disease in hormone-resistant patients with biochemical recurrence in prostate cancer Case report

Article Sidebar

PDF PDF (Język Polski)


Published: Apr 1, 2023
DOI: https://doi.org/10.24292/01.OR.131317323
Keywords:
non-metastatic castration-resistant prostate cancer, apalutamide

Main Article Content

Bartosz Dąbek
Chemotherapy Day Unit, Regional Hospital in Koszalin

Abstract

Treatment of non-metastatic castration-resistant prostate cancer is a radically new option for cancer patients. Novel anti-hormonal therapy not only improves metastasis free survival but overall survival times and positively impacts quality of life. This case shows how apalutamide lowered tPSA level and postponed metastatic disease.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Dąbek B. Apalutamide as a new option for postponing metastatic disease in hormone-resistant patients with biochemical recurrence in prostate cancer. OncoReview [Internet]. 2023Apr.1 [cited 2024Nov.22];13(1(49):24-6. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/2790
Issue
Vol 13 No 1(49) (2023)
Section
SUPPORTIVE CARE IN ONCOLOGY

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Siegel RL, Miller KD, Wagle NS et al. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1): 17-48. http://doi.org/10.3322/caac.21763.
2. Smith MR, Saad F, Chowdhury S et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378: 1408-18. http://doi.org/10.1056/NEJMoa1715546.
3. Hussain M, Fizazi K, Saad F et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018; 378: 2465-74.
4. Fizazi K, Shore N, Tammela TL et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019; 380: 1235-46. http://doi.org/10.1056/NEJMoa1815671.
5. Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative- intent surgery or radiotherapy (proPSMA ): A prospective, randomised, multicentre study. Lancet. 2020; 395: 1208-16. http://doi.org/10.1016/S0140-6736(20)30314-7.
6. Afshar-Oromieh A, Holland-Letz T, Giesel FL et al. Diagnostic performance of (68)Ga-PSMA -11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017; 44: 1258-68. http://doi.org/10.1007/s00259-017-3711-7.